Y2L C1 IgM ), (M onoclonal an tibody,m ab, ) M ab, M ab. , Feodo rova V A [1 ] M ab. M ab. (M onoclonal an tibody therapeu tics) cep tin M ylo targ

Transcript

1 34 8 ( ) V o l. 34 N o Jour. of N o rthw est Sci2T ech U niv. of A gri. and Fo r. (N aṫ Sci. Ed. ) A ug Ξ,,,, (, ) [ ],,,,, [ ] ; ; [ ] R [ ] A [ ] (2006) ,,,,, (M onoclonal an tibody,m ab, ), M ab M ab, 20, Feodo rova V A [1 ] (Y ersin ia p estis) M ab M ab (M onoclonal an tibody therapeu tics),, M ab [2 ] 1997, R ituxan H er2 cep tin M ylo targ,m ab, [325 ] 1 M ab M ab 2 : M ab, M ab ; M ab, ( Imm unocon jugate), M ab ( ) 2,,,, M ab M ab [628 ] 1. 1 M ab : Χ Β Α (EC) Χ, ; 2M ev Β 1 cm,, Β,, ; Α, 90 Λm,, ; EC, 20 Λm 186 R e, 67 Cu, 131 I, 90 Y, 212 B i, 213 B i 212 Pb,,,,, [9 ] M ab, CYT 2356 M ab [10 ] 90 Y M ab ( 90 Y2L C1 IgM ), Ξ [ ] [ ] ( ) ; (91033) [ ] (1982- ),,,, E2m ail: lwm @ 163. com [ ] (1967- ),,,,, E2m ail: tdw 4114@nw suaf. edu. cn

2 8 : 45,, 90 Y2L C1 IgM, 90 Y2L C1 IgM 90 Y Β (64 h) Zr, [9, 11 ] [12 ] 131 I M ab3h 11, 16,, 75% ( 12 ),,, M ark S K [13 ], 131 I M ab 59,, 42 (71% ), 20 (34% ), , 4,M ark S K [14 ] 131 I M ab 76 g g,, 75 cgy (1 ),, 95%, 75% ; 5, 51% 5,, , M ab,,, 1. 2 M ab 20 70,, g,, M ab [15 ] M ab,,, 6. 4 ku, 2 A (R icin A chain, R TA ) B (R icin B chain, R TB ) R TA, 3. 2 ku; R TB, 3. 4 ku,, R TA R TB [16 ] R TB,,,, B M ab,, [17 ] R TA M abhcm 2 ca b83, 0. 1 mo lgl, HR 8348, mo lgl,,, (A b rin),, A B 2, 2 [18 ] 3 : B ; ; A, 60S 28SrRNA 4 324, 2,, W aw rzynczak E J [19 ] M ab A,, 10 pmo lgl 50%, 1 nmo lgl 99% A, B,, A M ab,, 50% 50% ΛggmL,, 96. 3%,, 16, A [20 ] 1. 3 M ab M ab M ab,,

3 46 ( ) 34, M ab, M ab, [21 ] [22 ] M ab7a, T 10,, 0. 6 Λg, 1. 2 Λg,, M ab,,, [23 ] H 22 H T 229, M ab3a 5 (PYM ) 3A 52PYM,, M ab3a 52PYM H 22, PYM,, 3A 52PYM H T 229, 3A 52PYM M ab PYM 1. 4 M ab M ab 2M ab M ab, M ab2,,,,, M ab2, M ab G2 MM C1,M ab A 2Α2,M ab,m ab Β2,M ab 52,M ab Β2 [24 ] [25 ] 2Α2 M ab, 2Α2 (M TX2Α2Phe) 2Α2 (M TX2Α2A rg), M ab2 A,,,, M ab2 A 72 h, [26 ], (CEA ) M ab Β2, L ov o,, 2CEA M ab2β2, 40, CEA L ov o M ab,, 1. 5 M ab (pho todynam ic therapy, PD T ),,,,, [27228 ] [29 ] 2 (H PD ), (EDC I) CEA M ab (C50M ab), H PD 2C50M ab,,, H PD 2 C50M ab CEA 2 M ab M ab M ab M ab M ab M ab, M ab,, M ab, M ab M ab M ab,, 2, M ab, 1 M ab, M ab, [30 ] ED TA 90 Y 90 Y, D T PA 90 Y M ab;

4 8 : 47, M ab, M ab, M ab, [31 ] M ab Fc, (D T T ) M ab Fab, T 240 (D ex tran T 240) Fab (PYM ) Fab 2PYM [23 ] D ex tran T 240 M ab, M ab, M ab, 3 M ab M ab, M ab M ab,,,,, FDA R ituxan,, 60% M ab 20 90,, 2001, 11 ; , 123, 23 g M ab (H um an2an ti2mou se an tibody, HAM A ) M ab M ab, HAM A, HAM A M ab [32 ] ;, (V ascu lar leak ing syndrom e, VL S) ;,,,M ab,,,,,, ( ) [33 ] M ab [ ] [ 1 ] Feodo rova V A, D evdariani Z L. D evelopm ent, characterisation and diagno stic app lication of monoclonal antibodies against Yersinia pestis fibrino lysin and coagulase[j ]. J M ed M icrobio l, 2000, 49: [ 2 ] H ainswo rth J D. M onoclonal antibody therapy in lympho id m alignancies[j ]. O nco logist, 2000, 5: [ 3 ] D ickm an S. A ntibodies stage a com eback in cancer treatm ent[j ]. Science, 1998, 280: [ 4 ] W einer L M. A n overview of monoclonal antibody therapy of cancer[j ]. Sem in O nco l, 1999, 26: [ 5 ] N iculescu2d uvaz İ T echno logy evaluation: gem tuzum ab ozogam icin, celltech group [J ]. Curr Op in M o l T her, 2000 (2) : [ 6 ] Guang Xu, How ard L M. Strategies fo r enzym egp rodrug cancer therapy[j ]. C linical Cancer Research, 2001 (7) : [ 7 ] N ap ier M P, Sharm a S K. A ntibody2directed enzym e p rodrug therapy: efficacy and m echanism of action in co lo rectal carcinom al[j ]. C lini2 cal Cancer Research, 2000 (6) : [ 8 ] V rouenraets M B, Gerard W M. T argeting of A lum inum (g ) ph thalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: imp roved efficacy in pho todynam ic therapy[j ]. Cancer Research, 2001, 61 (5) : [ 9 ],,,. M ab [J ]., 2002, 25 (5) : [ 10 ],. 90 M abl C1 [J ]. :, 2003, 30 (2) : [ 11 ] T hom as M C, Ying Z L. T herapeutic advantage of 90 Yttrium 2versus 131 Iodine2labeled PAM 4 antibody in experim ental pancreatic can2 cer[j ]. C linical Cancer Research, 2001, 7: [ 12 ],,,. 131 I23H 11 [J ]., 2001, 10 (3) : [ 13 ] M ark S K, Judith E. Radio imm uno therapy w ith iodine 131 I to situmom ab fo r relap sed o r refracto ry B2cell non2hodgk in lymphom a: updat2 ed results and long2term fo llow 2up of the university of M ichigan experience[j ]. B lood, 2000, 96: [ 14 ] M ark S K,M elissa T. 131 I2to situmom ab therapy as initial treatm ent fo r fo llicular lymphom a[j ]. T he N ew England Journal of M edicine,

5 48 ( ) , 352 (5) : [ 15 ] Ram nath V, Kuttan G, Kuttan R. A ntitumo r effect of abrin on transp lanted tumo rs in m ice[j ]. Indian J Physio l Pharm aco l, 2002, 46: [ 16 ] Funatsu G, Funatsu M. Separation of the two constituent po lypep tide chains of ricin[j ]. D A gric Bo il Chem, 1977, 11 (7) : [ 17 ],. HCM ca b83: R icin [J ]., 1991, 5 (3) : [ 18 ] O lsnes S, Sanxlvig K, E ik lid K, et al. P roperties and action m echanism of the toxic lectin modeccin: interaction w ith cell lines resistant to modeccin, abrin, and ricin[j ]. J Sup ramo l Struet, 1978, 9 (1) : [ 19 ] W aw rzynczak E J,W ittke Z R,W aibel R, et al. M o lecular and bio logical p roperties of an abrin A chain imm uno toxin designed fo r therapy of hum an sm all cell lung cancer[j ]. J Cancer, 1992, 66: [ 20 ] T sai L C, Chen Y L, L ee C, et al. Grow th supp ression of hum an ao lo rectal carcinom a in nude m ice by monoclonal antibody C272abrin A chain conjugate[j ]. D is Co lon Rectum, 1995, 38 (10) : [ 21 ] Puja S, Rhona S. A nti2cd 74 antibody2doxo rubicin conjugate, IMM U 2110, in a hum an m ultip le m yelom a xenograft and in monkeys[j ]. C linical Cancer Research, 2005, 11: [ 22 ],,,. M ab [J ]., 1997, 8 (3) : 125. [ 23 ],,,. M ab [J ]., 1997, 32 (9) : [ 24 ],. - [J ]., 2000, 7 (1) : [ 25 ],,,. 2Α2 [J ]., 2000, 7 (3) : [ 26 ],,,. 2CEA 2Β2 L ov o [J ]., 2005, 12 (2) : [ 27 ] Bow n S G, Rogow ska A Z. Pho todynam ic therapy fo r cancer of the pancreas[j ]. Gut, 2002, 50: [ 28 ] A lfred M, F lo rian T. Pho to sensitization w ith hem atopo rphyrin derivative compared to 52am ino laevulinic acid fo r pho todynam ic therapy of esophageal carcinom a[j ]. A nn Tho rac Surg, 2001, 72: [ 29 ],. 2 M ab [J ]., 2002, 22 (1) : [ 30 ],. 90 Y O S M ca b [J ]., 2000, 21 (2) : [ 31 ],. M ab Fab [J ]., 2001, 81 (4) : [ 32 ],,,. [J ]., 2002, 1 (1) : [ 33 ] Kim J A. T argeted therap ies fo r the treatm ent of cancer[j ]. Am J Surg, 2003, 186 (9) : A dvance on m onoclonal an tibody therapeu tics fo r tum o r L IU W en-m ing, TONG D e-wen,l IL i, X ING M ing-hui, ZHAO Jun (Colleg e of A nim al S cience and T echnology,n orthw est A & F U niversity, Y ang ling, S haanx i , Ch ina) Abstract: M onoclonal an tibody therapeu tics p repared by techn iques of lymphocytic hyb ridom a and gene engineering has been an impo rtan t ro le in b io techno logical m edicines. E specially fo r tumo r, a great deal of p rogress has been m ade. T he an titumo r effects of monoclonal an tibody therapeu tics have been deter2 m ined by a lo t of researches fo r several years and p rovided crucial base fo r tumo r therapy. In the fo llow ing paper, the types, p reparation, u sage and lim itation of monoclonal an tibody therapeu tics fo r tumo r w ere summ arized and the app lication p ro spect w as fo recasted. Key words: monoclonal an tibody; monoclonal an tibody therapeu tics; tumo r